Singapore woos growth firms with plans to make SGX-Nasdaq dual listing easier

Singapore’s central bank will ease dual listings on the SGX and Nasdaq by creating a ‘dual listing bridge’—a prospectus disclosure framework aligned with U.S. standards that allows issuers to use a single set of offering documents—targeting Asian companies with market capitalisations of at least S$2 billion (about $1.5 billion) and due to launch by mid-2026. The move is part of a broader equity-market push that includes a S$30 million Value Unlock programme, nearly S$4 billion of market-development allocations (S$2.85 billion managed by six asset managers including BlackRock), and reforms to minimum share lots, post-trade custody and market-making incentives to lower execution costs. Regulators say the measures are intended to make Singapore a more attractive listing venue for high-growth firms, deepen access to U.S. capital and boost IPO activity—Singapore has already raised over S$2 billion this year and large listings such as UltraGreen.ai (~$400m) and potential biotech listings are in the pipeline, suggesting higher issuance and liquidity ahead.

Analysis

Singapore's central bank (MAS) and the SGX announced a 'dual listing bridge' to align prospectus disclosure with U.S. standards and allow a single set of offering documents for issuers listing on SGX and Nasdaq; the programme targets Asian companies with market capitalisations of at least S$2 billion (about $1.5 billion) and is expected to go live by mid-2026. SGX said the bridge will simplify the dual listing process and MAS deputy chairman Chee Hong Tat framed it as a way for firms with Asian operations and investor bases to tap deeper U.S. capital pools while improving investor engagement.

The move sits inside a broader equity-market push that includes a S$30 million Value Unlock programme, plans to cut minimum share lots, modernise post-trade custody and enhance market-making incentives, and S$2.85 billion to be managed by six asset managers including BlackRock and Lion Global as part of nearly S$4 billion in allocations. MAS highlighted a rebound in IPO activity with more than S$2 billion raised this year; DBS projects full-year proceeds of S$2.5–2.6 billion and the pipeline includes large upcoming listings such as UltraGreen.ai (~$400 million) and Gene Solutions (~$100 million pre-IPO).

The policy package should materially improve Singapore's attractiveness for larger, high-growth Asian issuers and help deepen liquidity and price discovery on SGX, while the asset-management allocations provide an institutional demand backstop. Key constraints are the S$2 billion market-cap floor and a mid-2026 implementation timeline that limit near-term impact, and issuer choice between Singapore and alternative venues (e.g., Hong Kong) remains a gating risk for the pace of new listings.

Key Decisions for Investors

• Monitor MAS implementation milestones and the prospectus framework rollout through mid-2026 as primary catalysts for increased cross-listings, watch regulatory details that affect disclosure equivalence
• Evaluate selective exposure to upcoming large Singapore IPOs and SGX-listed mid-caps (track UltraGreen.ai and Gene Solutions) as potential beneficiaries of increased U.S. investor access
• Consider tactical exposure to institutional participants and service providers named in the programme (monitor BlackRock and market-making/custody infrastructure flows) given their role in managing allocations and supporting liquidity
• Avoid assuming broad market uplift for smaller issuers below the S$2 billion threshold and maintain hedges or position limits until the bridge is operational and issuance trends confirm a sustained pickup